A phase II, randomised, double-blind, placebo-controlled, multi-centre study to investigate the impact of Diamyd on the progression of diabetes in patients newly diagnosed with type 1 diabetes mellitus.

Trial Profile

A phase II, randomised, double-blind, placebo-controlled, multi-centre study to investigate the impact of Diamyd on the progression of diabetes in patients newly diagnosed with type 1 diabetes mellitus.

Completed
Phase of Trial: Phase II

Latest Information Update: 02 Feb 2015

At a glance

  • Drugs GAD65 vaccine (Diamyd) (Primary)
  • Indications Type 1 diabetes mellitus
  • Focus Therapeutic Use
  • Sponsors Diamyd Medical AB
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 12 Jul 2011 EudraCT reports actual initiation date 13 Dec 2004, actual end date is 13 Dec 2011.
    • 12 Jul 2011 New source identified and integrated (European Clinical Trials Database)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top